1INTRODUCTIONWorldwide, hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed solid cancer and the third leading cause of cancer‐related mortality. If HCC cannot be completely removed, it usually grows very rapidly, resulting in a short overall survival (OS), ranging from 4 to 7 months. In recent years, owing to the advance of clinical staging systems, the therapeutic strategy of HCC has improved drastically, with many novel therapeutic modalities under clinical investigation. At this time, complete remission can be achieved for HCC patients by either surgical removal or nonsurgical ablation if diagnosed in the early stage, albeit a high recurrent rate of approximately 70% remains. Liver transplantation is considered to be the best treatment in some selected patients who fulfilled designated criteria, because the tumor and adjacent microinvasion were completely removed and most importantly, the cirrhotic liver was replaced. On the other hand, for patients with unresectable HCC, it is still debatable as to which treatment should be considered the “standard therapy.” In HCC patients without main portal vein thrombosis (PVT) or extrahepatic metastasis, namely Barcelona Clinical Liver Cancer (BCLC) stage B, transcatheter arterial chemoembolization (TACE) is believed to be an effective palliative treatment. For patients with BCLC stage C,
Asia-Pacific Journal of Clinical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud